0001628280-21-024899.txt : 20211213 0001628280-21-024899.hdr.sgml : 20211213 20211213095636 ACCESSION NUMBER: 0001628280-21-024899 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20211213 FILED AS OF DATE: 20211213 DATE AS OF CHANGE: 20211213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MorphoSys AG CENTRAL INDEX KEY: 0001340243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38455 FILM NUMBER: 211487195 BUSINESS ADDRESS: STREET 1: SEMMELWEISSTR. 7 CITY: PLANEGG STATE: 2M ZIP: 82152 BUSINESS PHONE: 49 89 89927-0 MAIL ADDRESS: STREET 1: SEMMELWEISSTR. 7 CITY: PLANEGG STATE: 2M ZIP: 82152 FORMER COMPANY: FORMER CONFORMED NAME: MORPHOSYS AG DATE OF NAME CHANGE: 20050929 6-K 1 a211213_6kxmorphosysandinc.htm 6-K Document

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

FORM 6-K

REPORT OF A FOREIGN ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For December 13, 2021

_______________Commission File Number 1-38455_______

MorphoSys AG

Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):





Exhibits

99.1    MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    MORPHOSYS AG (Registrant)

Date: December 13, 2021    By:    /s/ i.A. Thomas Biegi
        Name: Thomas Biegi
        Title:    Head of Corporate Communications    
    

    By:    /s/ i.A. Robert Mayer    
        Name: Dr. Robert Mayer
        Title:    Director Investor Relations     


EX-99.1 2 a991_exhibit.htm EX-99.1 Document
image_0.jpgimage_1.jpg


Media Release


MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies
Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2

BOSTON, Mass., USA and WILMINGTON, Del., USA – December 11, 2021 MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (NASDAQ:INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi®) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These treatments include polatuzumab vedotin plus bendamustine and rituximab (Pola-BR), rituximab plus lenalidomide (R2), and CD19 chimeric antigen receptor T-cell (CAR-T) therapies. The data, which builds on the primary analysis presented at the 2021 Annual Meeting of the Society of Hematologic Oncology (SOHO 2021), will be presented as an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), held December 11-14, 2021 in Atlanta, Georgia and virtually.

“In this retrospective cohort analysis, a statistically significant OS difference was observed, favoring tafasitamab plus lenalidomide over pola-BR and R2 in patients with relapsed or refractory DLBCL who are ineligible for transplant – a traditionally difficult-to-treat population,” said Grzegorz Nowakowski, M.D., Professor of Medicine and Oncology at the Mayo Clinic, and lead investigator for the RE-MIND2 study*. “I am encouraged by the OS difference favoring tafasitamab plus lenalidomide and the comparable OS between tafasitamab and lenalidomide and CAR-T, specifically the potential prolonged survival benefit the tafasitamab plus lenalidomide combination may offer my patients.”

Findings from the RE-MIND2 study presented at ASH 2021 indicated that tafasitamab plus lenalidomide resulted in statistically significant differences across several endpoints. Specifically, results showed:
The primary endpoint, overall survival (OS), was met with significant improvement observed for tafasitamab plus lenalidomide at 20.1 months compared to Pola-BR at 7.2 months (p=0.038), and 24.6 months for tafasitamab plus lenalidomide compared to 7.4 months for R2 (p=0.014).
A comparable median OS benefit was observed with tafasitamab plus lenalidomide at 22.5 months compared to CAR-T at 15 months without statistical significance.
Objective response rate (ORR), a key secondary endpoint, was observed with statistical significance for tafasitamab plus lenalidomide at 63.6% versus R2 at 30.3% (p=0.013).
Tafasitamab plus lenalidomide also achieved significantly higher complete response rate (CR), a key secondary endpoint, at 39.4% versus 15.2% for R2 (p=0.0514).
While safety endpoints were not included in this study, the most common adverse events (AEs) associated with tafasitamab plus lenalidomide are feeling tired or weak, diarrhea,





cough, fever, swelling of lower legs or hands, respiratory tract infection and decreased appetite.
Of 3,454 patients enrolled from 200 sites, 106, 106 and 149 patients were treated with Pola-BR, R2 and CAR-T, respectively. For the comparative analysis, matched patient pairs were created using 1:1 nearest neighbor matching with a caliper. Matched pairs consisted of: tafasitamab + len vs pola-BR, n=24 pairs; vs R2, n=33; and vs CAR-T, n=37 pairs.

“The RE-MIND2 Study is an example of our continued commitment to generating practice relevant real-world evidence which, in general, more realistically captures the clinical heterogeneity in cancer and allows us expanded opportunities to dynamically assess the patient experience. These data indicate that tafasitamab plus lenalidomide is a meaningful option for patients and has the potential to become a future backbone therapy in DLBCL,” said Nuwan Kurukulasuriya, Ph.D., Senior Vice President, Global Head of Medical Affairs, MorphoSys.

“We are pleased to see the survival benefit for patients with relapsed or refractory DLBCL in the data from the RE-MIND2 study,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte. “As we continue to establish tafasitamab in combination with lenalidomide as the standard of care in second-line treatment for DLBCL, we look forward to exploring the body of clinical evidence and bringing this novel treatment to patients with DLBCL and potentially even to other indications.”

Presentations are available on the ASH website at https://www.hematology.org/meetings/annual-meeting; #183 (oral presentation).

In July 2020, the U.S. Food and Drug Administration (FDA) approved Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. This indication is approved under accelerated approval based on ORR. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The U.S. approval is based on an efficacy subgroup of 71 patients confirmed by central lab. The FDA decision represented the first approval of a second-line treatment for adult patients with DLBCL who progressed during or after first-line therapy.

About Diffuse Large B-cell Lymphoma (DLBCL)
DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwidei , characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with about 40% of patients not responding to initial therapy or relapsing thereafterii , leading to a high medical need for new, effective therapiesiii , especially for patients who are not eligible for an autologous stem cell transplant in this setting.

About RE-MIND2
The RE-MIND2 study is an observational, retrospective cohort study (NCT04697160) that compares outcomes with those from the L-MIND study for autologous stem cell transplant (ASCT)-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are treated with therapies recommended by the National Comprehensive Cancer Network/European Society for Medical Oncology (NCCN/ESMO). The study utilized real-world data to generate external comparators for patients in the L-MIND trial. The primary analysis of the study compared patient outcomes from L-MIND with matched patient populations treated with gemcitabine-oxaliplatin plus rituximab (R-GemOx), bendamustine and rituximab (BR) and pooled systemic NCCN/ESMO recommended therapies. The additional analysis evaluated tafasitamab in combination with lenalidomide versus Pola-BR, R2 and CAR-T therapies. Patients enrolled in the study were aged 18 years or older with histologically confirmed DLBCL and had received two or more systemic therapies for DLBCL, including one or more anti-CD20 therapy. The study’s primary endpoint is overall survival (OS). Secondary outcome measures include overall response rate (ORR), complete response rate (CRR), duration of response (DoR), event-free survival (EFS), progression-free survival (PFS), time to next treatment





(TTNT), treatment discontinuation rate due to adverse events and duration of treatment exposure.

For more information about RE-MIND2, visit https://clinicaltrials.gov/ct2/show/NCT04697160 .

About Tafasitamab
Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Europe, Minjuvi® (tafasitamab) received conditional marketing authorization in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Monjuvi® and Minjuvi® are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi® in the U.S., and marketed by Incyte under the brand name Minjuvi® in the EU.

XmAb® is a registered trademark of Xencor, Inc.






Important Safety Information
What are the possible side effects of MONJUVI?
MONJUVI may cause serious side effects, including:
Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get fever, chills, rash, flushing, headache, or shortness of breath during an infusion of MONJUVI.
Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding.
Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or develop any signs and symptoms of an infection.
The most common side effects of MONJUVI include:
Feeling tired or weak
Diarrhea
Cough
Fever
Swelling of lower legs or hands
Respiratory tract infection
Decreased appetite
These are not all the possible side effects of MONJUVI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:
Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.
You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.
Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.
Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.
You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see the full Prescribing Information for Monjuvi, including Patient Information, for additional Important Safety Information.

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya®, developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys’ antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys’ proprietary product Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has more than 600 employees. More information at www.morphosys.com or www.morphosys-us.com.

Monjuvi® and Minjuvi® is a registered trademarks of MorphoSys AG.





Tremfya® is a registered trademark of Janssen Biotech, Inc.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

MorphoSys Forward-looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Incyte Forward-looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s expectations regarding the use of tafasitamab for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), its ongoing clinical development program for tafasitamab, its L-MIND program, its diffuse large B-cell lymphoma (DLBCL) program generally and its further discussions with regulators regarding tafasitamab as a treatment for patients with DLBCL or for any other indication, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain, and other third-party providers and development and discovery operations; determinations made by the FDA, European Medicines Agency (EMA), or other regulatory authorities; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended September 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

*Dr. Nowakowski has provided consulting and advisory services to MorphoSys.
# # #

For more information, please contact:






MorphoSys

Media contacts
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 89927 26079
Thomas.Biegi@morphosys.com


Investor contacts
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, U.S. Communications
Tel: +1 617-404-7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1-857-772-0240
myles.clouston@morphosys.com

Incyte

Media contacts
Catalina Loveman
Executive Director, Public Affairs
Tel: +1 302 498 6171
cloveman@incyte.com

Investor contact
Christine Chiou
Senior Director, Investor Relations
Tel: +1 302 274 4773
cchiou@incyte.com
Jenifer Antonacci
Senior Director, Public Affairs
Tel: +1 302 498 7036
JAntonacci@incyte.com



i Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209–16. doi.org/10.1016/j.beha.2018.07.014
ii Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253–265. doi.org/10.3747/co.26.5421
iii Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253–265. doi.org/10.3747/co.26.5421

GRAPHIC 3 image_0.jpg begin 644 image_0.jpg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end GRAPHIC 4 image_1.jpg begin 644 image_1.jpg M_]C_X 02D9)1@ ! @$!] 'T #_VP!# (! 0$! 0(! 0$" @(" @0# @(" M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_ MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P 1" $/ ^(# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]^]X]#1O' MH:3/H1CM1GU(QWI7 7>/0T;QZ&DR>Y'O2YXX(]J+@&\>AI'Y7BE&".!2X'I2 MYK=!-7&KD<%3UI2H/:DW$L *=3=MQ)-#=@]:7( X_2EH/ R!2NI(8F\=,&AA MN% )/.W\:"0#RU.-EL&XA55ZTN\>AHW+W.?PHP.P%*_D-*P;QZ&C>/0TF?4C MWI<\]1_]:G< WCT-&\>AI,^A'M2Y&>HQ1?K35[V&%%%%.^H"!2&SFEH MI&..U#5V*X;ESC-&\>AI-R9Z?I2C:?NXS1=A9(-X]#36!)S@TI#_ /ZJ500. M323NQB!.[&A2!P,FG4ULK@@4W>XD[CJ,#GBHRS9ZTH+9X-&H[)#@H'(%&YE+30JGH33N@Y-#3:%H%-*<\$4'+#3J*K8+L ,#%%&?:@G R:7 MNL%<*_);_@Z@_P"39X_^ND'_ *&:_6;X M:5LXI>IQ9A_NLC^>Z/\ U ^E+&3M(]Z2/_4#Z4)T_&OWOJSX3H.ILG^K;_=- M.ILC#8P'H:J6@4]V?M]_P:=@FT\5?]@V+_T:M?MTJ@]:_$;_ (-.CBS\5'_J M'1?^C5K]NDY!/O7X/Q0V\VD?<9;9X97 @-WIHPK%)-?.M2Z,[[ M1N*0'&:38?44HR,#'UI?PI+W=V4V(J8.32T44[]@$?[II$8#BE?[IIJ@DYI@ M/I#@]1WI:0[^PJ7)(!-@]:=3,/[TJANYHYD+4=1D>M(1P'!-+4>.<4_!YYHMYB;70"0.M)O4]C3L#'/-(2@."!^5+EB"8@"=S2 MJ%'0T93V_*E&.H%%[+8&DPHHH/M2T>Z!",I)R*38?44Z@YQQ5!>PW8?44H.T M8(- SCD4 8'S&DVT"=Q"4)YI5*]!WH^7..*,IV_E2YK]!V#=_LG\J/O# MP#US2A@:.:6]@L@V"E&>]!.*;O'>CWI"22!D[BE0$=:-PZYH8,3Q5)-JS!NR M%I"P'% ! ]:, ]5I>Z@5Q0<\BD"X;=FEI"P7K1IV&&X>M+3=R^E&]O2G9"LQ MU!.!FFXAI/E;DFFTJ[>]#?9A:+W';!ZFE P,49_SB@D M#DU*'YT'R\<,/SKAO^&B?@7_T5CP]_X.[? M_P"+H_X:)^!?_16/#W_@[M__ (NM_JN)_D?W&/MZ?<[E54C@YI=J?Y-<*/VB M_@6O ^+/AX?]QNW_ /BZ;_PT=\"PW/Q:\/?^#NW_ /BZ?U7$_P C^X/;0[G= M.VT84=/2D$K A2O4=:XJW_:%^"EWQ'6LZE*I27OIHN#4W>Y:60?>9L'N*1IE!X<5C>)O&GA;P MC8_VEXK\1V.G0G.'O;M(@<>AX?%?PY_X.[?_ .+I0HU90YHI MM#J2A#=GLE?E:0ZYU! M.U<@9-(LWS[6!QZU'#.)5R01^%'?_!W;_\ Q='U7$?R/[@]K'N=V'7G M#=* [!MK#CUK'\->,_#7C"T%_P"%=1 ME&5 V^]5+S7=+L$,E_J5O O]Z695_F:.5R>@:=676*@9_,4Y54J#C.:YF[^* M_P ,+#,>H_$;0H >\VKPK_-JH']H;X'1ML_X6UX=../^0W;_ /Q=:1P]=[)L MAU(KJ=HVT' -.&%&":Y.R^-OPAU)L6/Q0\.2-V"ZU 3_ .AUK6GB_P ,ZHH. MF^)M/N"3QY%ZCY_(U,H55IRL'5C;<[S MSVJ=MRHR4B0/QDFC<3VX[TT8)ZTV=GC'R]:AQN2N?C]\%;2[:SO/BCH,4B'$D4VL0*5_ OFM:<*E M1>ZKD3NNIVR3)@;G'US2EXF&0PKAO^&A_@3T'Q8\._\ @ZM__BZ/^&B/@7V^ M+'AW_P '5O\ _%UJL+B7O!_<9*K%;L[@.%&<\4XO\WWA]*X.X_:)^!PBX^+/ MA[&X=-:M\_\ H=2:?\?_ (+WE^ME9?%+0IY9CMBBBU>!F)]@'H^JUUJXNQHJ ME.3LF=L&1LD'IVI5DX^7&*K6T_GH)[9U>)UW*ZMG(IMS?6=I;F2ZNDA0=7D< M*/S-YI/DR!O&?2N"\=?M*_ WX$Q52-U!_<9.M03U M9]"9VGCF@LQ'(QGM7$^$OV@OA#XZMH[GPS\1=$G$F-J+JL)?GV#9KKUO(9(Q M);SK(#T96!!_&L*M.I0^)%*=.6S)@WS84\^E*9,+N9L>H-11R,%WR !CTQ33 M*V&$@&1VSUJ(M5%N(3]HKX&XX^*WAS_ ,'=O_\ %TC?M&? CO\ %?P[_P"#JW_^ M+JOJM>:MRO[B56BWN=R)X\<-D^@I&F(&XC%<,_[1?P+AB:3_ (6OX< 49S_; M=O\ _%UT?AWQ=X=\5Z7%K7AG6K6_MITW++:W"R+CZJ2*SG3J4E[T6C5.$]F: MQ=\X )_"G[L+ECBH$N5+%&;! SP:I7WB;P[I8,FK:_96P4\^?=(F/S-1%N>R M"RBKMFEYN!R>IXH5WR05KC]2^.?P;T]UBN_BEX>0NVU0=:@R#_WW5K3OBQ\. M-5;[-IWQ"T2X8=#!JL+D_DU:>PJ6^%V(=>FG8Z?><]*4$,.156RO[2^@$]K= M1RJ>C1N"#^53JV1D&LW!09:DI;#F51CZU^3'_!T^#_PS+&(_X9BCY_C@_]#->YPTV\YI>IR9BFL+(_GMC_P!0/I0G3\:103;@ M#TI8_N\U^^]6?!]!U-*;BP']TFG4U@23AL?(>:J6K%"]W8_;W_@U +"S\5L@ MS_Q+8OE_[:K7[">>:_$?\ X-/P6LO%3(1D:;%D?]M5K]L9'8'SD(R. M,9XK\%XJ?+FLK:GW&6?[LKE@-_ 6S28SRK 8-9&I^+_"^A@R:WXEL+-AU^TW MB1C_ ,>(KS3XB_MS?LV?#.X\CQ-\4M(#=,6VI0O_ ">O#I4<35E:,&=TI44U M=GL6]BW!X]:4EMNXMP*\@^&W[;_[-WQ1F:#PQ\4=(W1XR+C4H4SGZO7I6F^* MO#VNJ/[%UZSNP>/Q:FE5D[HI=W/7-8MEX]\%ZHWEZ?XPTJ8]O)U"-L_DU:,-Y#<']S,C\<%&!!_*L73E M]JYHG%KI:HC-C"RGGVI78IC!X-,"0L ,TH.>149IZ?=% VWJ M10 ,944TEFDVT2,8U %( 9R ",,:ANK^QLLO=WL,2=VDE"_ MS-.,8O9 W!+5ED%3SGBG"1<=<5S=_P#%#X;Z>QAU#Q_HT'?][JD*X_-JSI?V M@_@=:S"TE^*_AW>>.-:M_P#XNM/859_99"G2Z,[4O@9Z_2D#KR>_I7+0_&;X M33#,'Q1\.LIZ;=;@)_\ 0ZO6'CSP5J(']G>+]+N ?NF'4(W)_)JR<*J^RQ\T M6]&;>]CT'X4AD8=:CM[F*5-\,RN"."K TF3O+,WX4G&25RN5M%A6!%-9R.:8 MDF3P?RIT@W*23UIIV5Y M-PW.3NSQCI0LNXX#<^E97B'Q5H'A2Q.I>(]:MK& MW!VF6ZN%C7\V(%/ MF;\*870=ZX@?M%_ YC@_%GP[_P"#NW_^+I3^T5\"QP?BOX=_\'=O_P#%UM]5 MKK[+^XEUJ:ZG;JR'G=2*Z\C[Q'I7#R?M%? H#GXL>'ASVUJW_P#BZO>'OC%\ M+_%MY_97A;X@:/?7+G BL]3ADRJ[J+'[2"ZG4K(3P&SCK2B4G(QR.]< M[H_Q,^'WB6\.F^&?'6CWUPHW/%9:G%*P4^RL3700%9$XR".M9M<9'M3L*O/2H#*0=R$8J"YU73K(> M=>ZE!"/^FLRK_,U4)2GT!OS+I?/ XII_.N?N_BA\-]/RE_\ $+1(<=?.U6%? MYM64_P ?_@A!<_9W^+?AW=[ZW;__ !=;QHU);1?W$N5);R.V^3NW-!"XX/-< MO'\9?A%/@P?%/PX_^[K/)OXVS^34G2J1U<6" ME2;W-H,P'6EW;A@CCUJNETL^'MGC=#_$&R#4H8D!1C\ZRE*W0JZMH.! 88YS M^E/J*,@MM7MUJ6B+D]QA1115 ?Q1_P#"VOBG_P!#KJ/_ (%R?XTH^+7Q1[^- MM1_\"Y/_ (JL'Y_:D+L."*_I+ZO0_E1^>*M4O:YT!^+'Q0SSXXU 9[?:Y/\ M&D_X6M\3RV/^$YU#_P "Y/\ &N?)+$$F@*1(,T?5Z'\J)=>KRMW/4_V>?BC\ M2IOCIX:BF\;7[J=24,ING.>#[U_6U^R9/<7G[.WA.6[E9W;182SL>2<5_(1^ MSCD?'GPR/^HFO\FK^OG]DA=O[./A$_\ 4#A_E7YGQY2ITU#E5M3Z3)JDZD6I M'Y[_ /!T+XC\0>'_ -FG0KG0M7GM7\ZXRT$A4GY/8U_/E;?%CXHM:J/^$YU# MDT,Y_Y;7/\ Z!7\[UNH6U3']T5[7!="C4RM\T4] M3#-*DXUU%/2QT*?%;XGQC!\<:B3_ -?-M0_\ R3_ .*K M!()8G'YT,..!7V#PN'<;62Y8K8[LOK5'B$KG]*R%A$K8P=HK^9O_ (.$?'WCG0OVWGL= M#\3WEK%_9N3'%<.H^\/0U_3.@!A3_='\J_F&_P"#B0 _MSOG_H%_^S"OS7@V M$9YA+F5SWLT;A25F?$2_%KXI$X/CC4?_ ,D_P#BJ>OQ8^*#*?\ BN-1&!_S M^2?XU@!0#G% ;KCTK]B^KT;?"ON/E57JN5KFZWQ8^*&!CQQJ/_@9)_C3+CXM M_%#[.57QOJ/ _P"?R3_&L,G@4V5086)]#2J8>BH+W5KY$K$UN=*Y_2A_P;6> M(M9U_P#8_MKK7=5EN9C90[6FD+$_F:_25D4?,%.>XK\TO^#994_X8WM691\M MC#C%?I@Y929"0!CN:_ LZBEF-105M3[K"2DZ$6^PC %25X)[5YC^T)^UG\%/ MV:]&EUKXM^/+'2$ACWA+R0KNXSC@5\[?\%5O^"N'PJ_X)_>"9K7^T5O/$E[" MQLK.%/-"L"00P7)6OYS?VO?V\_C[^V!X^O/%GCOQ?>+:7#GRK"*Z8Q*F3M^4 M]#C%>QD/"^*S-\\](G/B\PIT%9/4_6O]M/\ X.E/!7A759_"G[/OA:?56!98 M]7LKM&C7T."0:^ ?C%_P7?\ VZ/B^D\-M\0)K*WD9ML1A&0#VR&KXBALXM[& M,#KSGJ:EAEEC8J,8K]*P?"> P=/6-V?-XG,,15G>+T/3/''[9/[27C]L>*OB M'>S$_>9)67^35R+?%OXIH,)XXU#DY_X_)/\ XJL-S)(W INTYR?QKVU_"/\ X*[_ +;?PHFB M?0_BK-(L39:,Q[BH]>6KYC+C' HVF!//'\7!QU-9XC+L'5CRSIEPQ&(@[IGZ MS_LR_P#!T?\ %SP?K-KI7QK\-7FNVI8+/=12QQK'T'.3^-?J[^R3_P %;_V3 M_P!K2TM8_#GQ*TVTU.=5SIC7!:0,>W QUS7\F\AMW7;M*ENV.M;GP_\ BCX_ M^$VO0:]X \075A8H#CIR*^8S3@W!8F+]C&S._#YG5A/WWH?VL6EU! M=0)-;3*Z.,HXZ$4^;;MP>?I7XJ?\$=?^#@'_ (2J]TS]G_\ :2N5BO@BPV%^ M 6$BC R[M@!B6%?LWH^L6FMV$&I6-PLL5Q&KHR,",$9'2ORO,)C[AE_%EFC^&6NM Q5QI%R58=OW35_(S^V3\3_B5;_M+^)(X?&E\B)= MOM1;IP!\[>AK^NCXM)_Q;'7R/^@-<_\ HEZ_CY_;2)'[37B?!_Y?'_\ 0VKZ M_@6E3JU9\RO8\O-ZDZ--.+.1/Q9^*);(\:ZC[?Z9)_C0/BS\4L\^-=1_\"Y/ M_BJP8RQ4ZE<&9X'#U,%*T5,[WX=_LQ M:C+I^C6\C(=2C=9$G7GIR".:X;_@N?\ \% O$/Q!O?#O[/O@;Q5/;V>29RS,L[J,D^F:Y#^TM<4[X]?OA+_?\ M;_XU"5=4W _ M*31GG-??4\+0ITU%17W'A^WJ2UOJ>@_"S]JOX]_!K7+?6?!/Q O8)8&!4O,[ M#@YZ$U^L7_!+/_@XP\2:AXRT_P"#O[5,TA@N)$ABUJYE6.(=,MC)-?BX<%MQ M%*TD\$J7,%S)$ZG,E>;F>0X#'T9)QUL=F$QE6$_>9_:KX0\9Z)XV M\.6?B/P]J4=S9WD*2P3QG((8 C]*TM1WFSF93M=8SD_A7XI?\&W?_!2WQ/XI MF;]FOXM^(7NY(5>2QEN9B[!!D(N3^'%?M?J(+:?* ./+//<\5^)9AEU7*\7[ M.7<^OA45?#W1_*G_ ,%C/B3\1-*_;EUJPTWQ?>PQ*C%4CN7 ^^>P-?,1^+/Q M14\>-]0^8_-_I/\ F=M1Q_U]R?XTS_A:WQ08Y'C;4?QNY/\ XJL- M6W<$4%@IP!7J+"X=._*ON.=8BJHZ,U=5^+7Q133IY_\ A-M1&V,X'VN3_&OZ M5?\ @WG\1:SK7[ ?A[6M8U.2>4Z3"\DLTA8_Q9ZFOYB];,B:;/G:Q,1R >U? MKM\)?^"B%W^QA_P1WT#0/"M\D>O:YX>A:P\IOG4!G5LXY!KXSBG+_;TX0I17 M,V>QE>)?LW*H?>/_ 4X_P""Z?P6_8PT^?P=X"O(M>\1ME'MK*Y >$D?>(;' M?-?B[^T+_P %K_VS_CUJUY=1^.;G2M/GV5:OEOQUXY\5?$SQ5<^ M,_&FL37MW>S-(SW,A9AN)..>PS62Y1I/L^21W)%=V4\,X+!48N4;R9S8O,:T MYV@]#K=4^/OQH\2W+ZMJGQ#OGE=B3BY<_MJ_M.?"RXCN_"/Q*O( MG0@_/(SY/XFO*E1@NQ.W.:>OF* 217T$L!A:T>5Q5O0XX8RLI;GZ;_L5_P#! MR'^T+\'M>T_0?CNUUKVDO*J2R(4C$2]V))Z5^[O[)O[8'PG_ &N?ASI_CWX9 M^([:Z%W;K)/;0R[FMV.?E8^O%?QU7LP:-=R@@'H17UA_P2P_X*/_ !$_8>^/ M6C7%UKUW/X:OIA'=6;.S(C.51?E'IS7Q'$'#%"4'4H1LSV,!F=ZG+-G]8,4J M8VNX#>E?DY_P=/$#]F:(#_GI!_Z&:_3GX/\ Q'T/XJ?#W3?'&@723Q7UI'(K MJ01N**2./K7YB?\ !TWN/[,L1<<[X,X_WS7Q'#D94\ZIQENF>SF#YL*V?SY1 M_P"H'TH3I^-)%_Q[CZ&E097'O7[W'63/A7HF./ SFFD>9D =%-./0U&58HQ5 ML<'G-3)MP)I/W]3]OO\ @U$*KI_BV<+Q_9D7/_;5:^QO^"I/_!9GX,_L->#; MG2/#6MV^K>)Y%V1Z9:W $J$_+NPV!P2*_+K_ ((T?M<:)^QO^R;\3/BI>W(6 M\@\.!].A/6219DXQU/&>E?GO^T9\>/%O[27Q8U+XJ>+-0EG:_NGE@AE._%-TUYXA\5WT\C'+,;I_\ &LYGE*XC Q[4G+)M?K7W MF R["8>-HP2L>/6QM6&[/ZGO^"6/_!7+X8_\%!/A_;F,+IOB2*%?M.DS MW :7><#''%?:T$C&(-(A4^AK^./]C;]L#X@?L6_&G2/BUX-O7C33[I9KJT#D M1S = P'6OZMOV&?VI='_ &LO@+I'Q0TJ0,T]K$+I0,;92@+ #ZU^-\29!+*J M[G%>Z?4Y=BO;1:DSVDE@N[;U[4C2A#MSSCD4AW)&VQLGMFOGG]O[]OGX8?L+ M?"2\\?>.=23[3Y;)9VJ .[2%?ERN<[XNF(4 ?05^9'[<7_ ,KZ^O?$5UI6@W$K&"RLIW12 MA[%2!7RV-H0GF1ADD^M?I62\%4[QGB4?.XS.$I*Y]+@ESM@DB4E1]0U?-GC_P#;R_:L^),CMXG^)]U(9,YV,R_R->/J MC,?-+#_@1I2?+&"/(EC:[5VS??XM?%+S3)/XYU!F;J1>2 M?_%58T?XW?%[0KT7]AX[U#>IRO\ I4G'_CUOAO_ ,%.?VROAK?1S>'_ (HW*+&?E5P6_FU?6?[//_!R]^U% M\*[^UM?BC!>>(+,.!,(=D?R_4M7YH(7.6.,T>>6&V6,<]\5YV+R#+,5JXHUC MCJ\4G%G]0'[%?_!>7]DK]J>UMM*UKQ+9>']6E"@Z?>7FZ0,>WR@U]RZ'KVE^ M(]-AU?1[^.XMI0&22/H01G^M?Q1Z'KVH>%-235?#6IW5C<1G<)[8E6S]17Z@ M_P#!)'_@O=X]^ ][IWP6^/>IR:CI%Q._!FHI=Z? MJ5L)HI P) ).,XZ=*Z8W;_<"]1\I(KX"<)4FU+<]VF_:QNBR\@4Y+8KD_B?\ M:/AY\'-!F\3?$+Q7:Z;9Q(6,URQ"\=>U>5?MU?MY?"C]B/X77?C/XBZNJ3K" M3;6\6'=V.0/ESDC(K^;O_@H3_P %:/C]^VSX^OKJW\1W6EZ )2MO:6,SHKJ" M1\R^XQ7O9)D6(S>5UHCS\9CH45RK<_6C]O#_ (.7/@1\%UN/"OP+M5\4:D"5 M^V:9>KB(],$-CU!K\VOC9_P<&_MN?%;S[;1?%T^G6LN=D+1*2H/N&KX'\L-> M&ZN7:2:4[FD?DD^]2@NDI&..U?I>6\-9;A%:4+R/GJN/JSZGK?CS]N;]J?XA MR/<>)/BE=2%LY5'9>OT-<,_Q=^*\K?:IOB!?L^<_\?YV>B_M"_'#2I//L?B3?(5/ :X<_^S5Z5\-O^"G' M[9?PJO89_#_Q5N B,-I8%L?F:\":/NM+$[<;%#;>NZHJ9=A*^G(DA?7*].6Y M^GW[.'_!SI^T=\*;J"W^+.A7WBBU5@LAMFCCP/7EJ_47]B;_ (+Q_LE?M906 MUAJGB:S\-:M<8 TZ^N]\A8]OE!%?R]S@JWF(.#U4=*L:)K>K^&M034_#NK3Z M=<(V4GLWVN#]17SF8<'Y?B>:5)69WTLUKPFK[']KFAZWI?B"PCU31-0CN8)D M#1R1GA@>]:"S+GYF&.Q]:_G=_P""0W_!>WQ;\!?$=A\(/VB-6GO]"NI5A@U" M7=-,CL0B GLN3R>U?OU\./B/X9^*?@^U\;>$=4AN[*]B#PR0RJXQCV)K\JSK M)L3E-:TUH?3X3%0Q,#X[_P""_NJ:KHW[%]]J&C7\MO,MVF)(G*GH?2OYD8_B MO\4)W,G_ G&H+ESG_2Y/7ZU_3-_P<#OC]AZ_8_\_2?R-?R^0_-;[EX.]OYU M^B<#X>A/"2G.-V>'FU6MAZR2>AT)^*_Q17IXZU#Z?:Y/\:/^%M?% #)\;ZB? M^WN3_&L$;>Y-*NT]!7W7U;#N7PK[CPZF)JWW-U_BS\3W7CQMJ(]X-?HF5VKT[5^;__ !_]"-? MCV20B\T@GU9]-B;JC)KL?SI6WQY^,:P[/^$^U#:>F;=Q/-1]1PTX_"ON,_K.(C;E9^ ME?\ P;3_ !5^(WBK]O'6]$\2^*[N\MD\/Q.D37])22E!AF&?2OY MF?\ @V+ '_!0;7B!_P RW#_Z&U?TPW#RQ#=&BD>]?C7%M*G1Q_+%:'V>7R]I MATWN/FFPI\KYCZ"N)^*_QW^&GP0T"3Q1\3O%EKH]M&F[S+MR 1SZ"O(/^"@? M_!0GX6?L+?"V[\5^,-8C.I/$XLK*,AW:3&1E0G>L'IZ;GZX_MW M?\',7P@^$WVGPK^SYIA\27R97[;IMXI5#ZD-CH17YM?&?_@O[^W%\6EE?3_& MD^FV\N0L#Q*2@/;(:OAL$SN;J1R9&/S/GEOK2G(<%ON^U?I^7\+97AHKFC=G MS-?-J]3X3U;QS^VY^U%\078^)?B?=R[R22CLO7Z-7"R_%WXK/<>;/XYU%F/< M7]$BEDPE:X MC+,)65I15BY5\1#6+/U"_9M_X.>OV@OA?-:Z7\7=!OO$=JK ,\+QQA??EJ_4 MK]C+_@NY^R)^U+:VUC?^,+'P]J\H -A>7>YRQ_W01UK^7)P_D&,HO(^8MVJ; MP]KVL^$;]-4\-:I<6,\; K/;OM;.?6OEL?P?@<3%^S5F>A3S6I3@KL_M>\.^ M(])\16*:MHE^EU!*H*2Q'@BM02J1D5_.5_P2*_X+S>/_ (!^+--^#/Q\U6;4 M-%O95@BU&B\#%?T#_#7XF^&?BQX(L?&GA#45N+*_@26.2-@>&'& M<'BOS#.,GQ.4U;36A]%A<93Q$$T==YGM15#['&>?MC_]]45XGM8'=[I_$Q2. M.*6D?[IK^G#\SB[R&CJ/K2G[X^E)V7ZTI^^/I0'V6=K^SB"?CSX9/7_B9K_( MU_7S^R2<_LX>$0/^@'#_ "K^0;]F[_DN_AK_ +":_P FK^OC]DC_ )-R\(_] M@.'^5?F''^U/U/ILBVD?G=_P=*9/[+^A+_TVN/\ T"OYX(.+5!["OZ(?^#I3 M_DV+0O\ KM<_^@&OYWH?^/9/I7N\$?\ (J?J89K_ +TO0D!))'I2T)]YOI17 MV+V/GW\0*,(17Z,_\&TPQ^W,../[$N/Y5^(/ _[#>H2:%?M ZY\5/$&JR20RWK2:?;.^?+5@,CTKQ@ M%H1A>XL8[AVRS+DDU:!+,*_;\+A*>#PL(4SXO&3G5KL79\PD"]=;3ON81OS6'L)8U$SKA3R">]4VUO3H MY3#/=JK>AK[;_P""(/[!'A/]O/XUWFF^/[N9=,TN]$3I XR1L5NA^M?N[X6_ MX(E?L2>']#CT]OA]:7+QQ >=/8QLQ./6ODLXXLPV65O9=3VL'E$YPZL1_2O7R3.:&;4G..IRUL//#R:D1A#,?, M8A9T74=4\.:G;Z MQHUVT=Y:3I/$Z'!!1@W\P*_I<_X-^/V_]1_:X_9JMO"GC2[,_B+1(6-W)))E MC&&5$X_"OYG(PQBV_P 0'WO6OUE_X-8O%>L6GQX\3:3;3E;6338%,8;_ *:G M/%?%\88&EB,N=>VJ9Z.45Y4JW(?O=\6C_P 6OU_/_0&NO_1+U_'S^V?_ ,G- M^)_^OQ__ $-J_L%^+W_),=?_ .P/=?\ HIJ_CZ_;0;/[3?BG7!^UV4HDM9E'W6K*;J #@^M- #,TRDE3USV^E14@JL.1E*I[&.O4U M/&WB_7_&OB23Q%J^I-)(=#EV>(]!O=/8?=^U6K1[O^^@*FC7P]"'(GJ;*'[G MFL5 WEOL>3"=U]Z"%(RII&6 191F+D]^E*J<<>E6V%=3T&9XFNM3MK>4(>JM( M:_KD2=[KP_\ :91AGA)/Y5_(!^P,"R/^A@M/_1JU_7Y:'/AE?\ K@?Y M5^2<=J+QE*21]5DE5U*#3/Y1?^"S1(_;OUP_[#_^AFOEIST)[U]2_P#!9S_D M^W7!_L/_ .AM7RRPR%'M7Z)DW^X4_D?/8Q?OV*IR.E)(2. *^E=K?0[$V\(+< ;B>GXUR8,2+ MYD@XQ6AH'@CQAXO)C\->$M3U!0?^7*Q>7'UV@UCB(X>7*YV^9K"5;FY((S96 M6:82,^YL8P.PH1F8- B;RQS@5TE_\&?B_IMJ;F\^%/B&*).6EDT:91CZE:YU MXC;RGSHI8Y(^)$92&4^A':J5>A%^[),TK4ZU!:H5@T8QOQ_LT995P6S3(SN^ M;)Z]ZG):?L2:=(&Y:YN.,_[2UYS_P ' M3BG_ (9FC('_ "T@_P#0S7X]AJ<*7%48Q[GV%2;GEGR/Y\8@?LX/UH3I^-+' M_P >B_C0F-OXU^RP^-GQSV8K?*.?PIAC,J;=^.>M.Y/WJ3:V[$8[=*2DHQNR M*:3D[G0Q?%'Q5;^#6\ V%^\%D4*RH.C@]OTKFU54BVD97/)]ZV&I?\(/JS6^W_71Z?(4^N<8KEA+#T:CFW:YM3]I7TBM$9N74 M@1 L/:G&16.,\^E-97B)\P%64\(>"#[BFNZM(!(IP>NT3_ (-3W8?" M;5H4Z?VA/_)J^2XUC[3*W)]#V,GJOZRXGZ]^,/%>D^#/#=UXFUVX6*SMHR\D MC' 45_+A_P %HO\ @HEKG[:_[2>HZ/H]_)_8.B3M9K;++N5GB[=Z\TN,'!K]9 MC"]SY22C>\B-X\MEC3FP6#8P>E$A&0 :];_8C_9QU']JS]HG1_A+9R)'#+

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